| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514387000 | Polycyclo ring system having the diazole ring as one of the cyclos | 30 |
| 20080221185 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders - The invention provides a compound of formula (I) or a solvate thereof: | 09-11-2008 |
| 20080249152 | Biotin Diaminoderivatives and Their Conjugates With Macrocyclic Chelating Agents - Formula (I) compounds are described: Formula (I) where the radicals are as defined in the description, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours. | 10-09-2008 |
| 20080269307 | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus - The invention relates to the use of the acetyl L-carnitine in association with the biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus. | 10-30-2008 |
| 20080319038 | PREVENTATIVE OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE - An agent for prevention and treatment of acute renal failure comprising a hydantoin derivative represented by the general formula below as an active ingredient. One example of such compounds is (2S, 4S)-6-fluoro-2′,5′-dioxospiro[chroman-4,4′imidazolidine]-2-carboxamide. | 12-25-2008 |
| 20090062360 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof - Compounds of formula (I) and salts and solvates thereof are provided: | 03-05-2009 |
| 20090082415 | Topical treatment of cataracts in dogs - The topical treatment of cataracts in dogs is a composition having an aldose reductase inhibitor (ARI) in a topical carrier. The ARI is preferably 2R,4S-6-fluoro-2-methyl-spiro[chroman-4,4′-imidazolidine]-2′,5′-dione, referred to as 2R-methyl sorbinil, having the structure: | 03-26-2009 |
| 20090163565 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof - Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is the process for their preparation and pharmaceutical compositions comprising them, useful for the treatment of cognitive deficits, and of various types of pain. | 06-25-2009 |
| 20090176851 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 - The present invention relates to a new use of spiro-hydantoin derivatives of formula (I), or salts, solvates or solvated salts thereof, as well as to new compounds, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy. | 07-09-2009 |
| 20100056591 | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators - Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed. | 03-04-2010 |
| 20100087497 | Benzimidazole Anthelmintic Compositions - The present invention provides a veterinary anthelmintic composition that includes: at least 10% w/v of a benzimidazole anthlemintic; and b) a water-immiscible solvent system, which comprises a lactone solvent, an essential oil, and surfactant. | 04-08-2010 |
| 20100087498 | USE OF BIOTIN TO PREVENT PHOTOAGING - Use of biotin, preferably in a combination of biotin and (-)-epigallocatechin gallate (EGCG) in a specific ratio, to prevent sunlight-induced aging (photoaging) of the skin. | 04-08-2010 |
| 20100120880 | PROCESS TO PREPARE NEW SUBSITUTED 1H-BENZO[d]IMIDAZOL-2(3H)-ONES, NEW INTERMEDIATES AND THEIR USE AS BACE 1 INHIBITORS - The invention relates to a new process leading to new substituted 1H-benzo[d]imidazol-2(3H)-ones of formula III and III′, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly as BACE 1 inhibitors in the treatment of Alzheimer disease. | 05-13-2010 |
| 20100273847 | DESFERRIOXAMINE CONJUGATES, DERIVATIVES AND ANALOGUES - The present invention relates to desferoxamine conjugates, derivatives and analogues thereof. In particular, the present invention relates to desferoxamine conjugates, analogues and derivatives thereof, and methods for reducing levels of metals, especially iron, in a mammal. Uses of the compounds according to the invention are also provided. Compounds of the present invention may also be used to treat iron dyshomeostasis disorders, cancer, malaria and fungal infections. The compounds of the invention may be formulated into a pharmaceutical composition or packaged into kits. | 10-28-2010 |
| 20100292287 | Periodontitis treatment - The periodontitis treatment is a method for the prevention and treatment of periodontitis in mammals, including humans and dogs. The mammal may be diabetic or non-diabetic. the method includes the step of administering an effective amount of an aldose reductase inhibitor (ARI). The ARI may be (i) a phenolic derivative, such as quercetin, quercitrin (a 3-oxy-glucose analog of quercetin), rutin, and other polyphenols or bioflavonoids exhibiting an ARI effect; (ii) an acetic acid derivative, such as tolrestat, ponalrestat, etc.; (iii) a cyclic imide (or hydantoin), such as sorbinil, 2-methyl sorbinil, imirestat, etc.; and (iv) one of the phenylsulfonyinitromethtane derivatives, such as ZD-5522. In particular embodiments, the method may include, e.g., administering a diet containing about 0.08% quercetin (about 80 mg/kg/day), about 0.0125% imirestat (about 12 mg/kg/day), or about 0.015% tolrestat (about 20 mg/kg/day). | 11-18-2010 |
| 20100317704 | SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER - Compounds of formula (I) and salts thereof are provided: | 12-16-2010 |
| 20110251249 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS - The invention relates to compounds having the formula: | 10-13-2011 |
| 20110251250 | USE OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN - The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed. | 10-13-2011 |
| 20120004273 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - Disclosed herein are compounds of formula (I) and: | 01-05-2012 |
| 20120122943 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents - Melampomagnolide B is disclosed as a new antileukemic sesquiterpene. A biotin-conjugated derivative of melampomagnolide B was prepared to elucidate its mechanism of action. Prodrugs of Melampomagnolide B are disclosed. | 05-17-2012 |
| 20130210875 | Novel binding site of IKK-beta - Uses and applications derived from the discovery of a novel binding site of IKK-β, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided. | 08-15-2013 |
| 20130281503 | MODULATION OF RESPONSE REGULATORS BY IMIDAZOLE DERIVATIVES - The present disclosure provides methods and compositions useful for screening agents for activity in modulating response regulator signaling activity, which is, in turn, useful for determining whether these agents modulate biofilm formation or lowers the minimum inhibitory concentration (MIC) of an antibiotic, useful in determining or selecting optimum agents and/or agent dosages in modulating a biofilm of interest or lowering the minimum inhibitory concentration (MIC) of an antibiotic, and useful as a research tool for studying response regulators. | 10-24-2013 |
| 20160074370 | METHODS OF INHIBITING CATARACTS AND PRESBYOPIA - Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a γ-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins. | 03-17-2016 |
| 20170231905 | METHODS OF INHIBITING CATARACTS AND PRESBYOPIA | 08-17-2017 |
| 514388000 | Nitrogen double bonded directly at 2-position of the diazole ring, or tautomeric equivalent | 7 |
| 20080249153 | ANTHELMINTIC FORMULATIONS - This invention relates to the preparation of veterinary anthelmintic formulations including triclabendazole in solution, particularly for the treatment of parasitic infections such as fasciolisis, and particularly for administration to an animal in the form of a pour-on. The solutions may include triclabendazole dissolved in a solvent system including at least one solvent selected from 2-pyrrolidone and liquid polyethylene glycol. Additional solvents may also be included. The present invention is advantageous as triclabendazole can be included in solution up to a concentration of about 60% w/v allowing for an effective dose to be delivered to the animal in a volume of 25 ml or less. | 10-09-2008 |
| 20080275098 | NOVEL SUBSTITUTED 2-AMINOIMIDAZOLES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENT OR DIAGNOSTIC AID - The present invention comprises novel substituted 2-aminoimidazoles of formula I, processes for their preparation, pharmaceutical compositions thereof, and methods for their use in the treatment of disorders of the central nervous system, cardiovascular disorders, stroke and pulmonary disorders, urinary disorders such as acute or chronic renal failure, disorders of biliary function, respiratory disorders such as snoring or sleep apnea. | 11-06-2008 |
| 20100280087 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS - This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 11-04-2010 |
| 20130041002 | DENIBULIN DI-HYDROCHLORIDE - MN-029 di-hydrochloride (MN-029.2HCl, Formula 2) is a potent vascular targeting agent. | 02-14-2013 |
| 20130143936 | 2-IMINOBIOTIN FORMULATIONS AND USES THEREOF - The disclosure relates to improving the aqueous solubility of 2-iminobiotin. In a particular aspect, the invention pertains to formulations suitable for administration of 2-iminobiotin to mammals suffering from disorders or conditions that benefit from said administration. | 06-06-2013 |
| 20130245085 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 09-19-2013 |
| 20130345273 | REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK USING NOVEL MOLECULAR CONTAINERS - Provided are methods for reversing the effects of agents used for muscular immobilization and/or loss of consciousness and/or loss of pain perception. The method comprises administering a composition comprising acyclic CB[n]-type compounds to an individual in need of reversal of the effects of neuromuscular blocking agents and/or anesthetic agents such that the effects of the agent(s) are partially fully reversed. | 12-26-2013 |
